Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that senior management will participate in TD Cowen 45^th Annual Health Care Conference and Leerink Partners Global Healthcare Conference 2025. Members of Alterome management will participate in one-on-one investor meetings at both conferences. Details of participation are as follows:

TD Cowen 45th Annual Health Care Conference

Date: March 3

Location: Boston, MA

Leerink Partners Global Healthcare Conference 2025

Date: March 10

Location: Miami, FL

About Alterome Therapeutics, Inc.

Alterome Therapeutics, Inc. is a clinical-stage precision oncology biotechnology company developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in development for solid tumors: ALTA2618, a first-in-class, oral mutation-selective inhibitor for AKT1 E17K-driven cancers, and ALTA3263, a best-in-class, oral pan-KRAS isoform-selective inhibitor for KRAS-driven cancers. Alterome has raised more than $231 million in venture capital to date and is led by a team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs.

For more information, visit www.alterome.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225983962/en/